Skip to main content

Advertisement

SpringerLink
Log in

Bridging antiplatelet therapy in patients requiring cardiac and non-cardiac surgery: from bench to bedside

  • Published:
Journal of Cardiovascular Translational Research Aims and scope Submit manuscript

ABSTRACT

Dual antiplatelet therapy (DAPT) is the mainstay of pharmacotherapy after an acute coronary syndrome or percutaneous coronary intervention. While patients requiring interruption of DAPT at the time of cardiac or noncardiac surgery face an increased risk of thrombotic complications, the opportunity of continuing DAPT in the perioperative period should be balanced against the risk of bleeding. Tailoring antiplatelet therapy on patient- and surgery-specific characteristics mandates a clear understanding of pharmacodynamic and clinical data on using antithrombotic agents in the perioperative period. This is also important given the introduction of novel antiplatelet agents that are already adopted in practice (prasugrel, ticagrelor) or will likely be adopted in the near future (cangrelor). This article explores the theoretical background and rationale for bridging patients on antiplatelet drugs to their surgical procedure, and provides insights on how patient and procedural characteristics translate into different considerations for the use of antithrombotic agents in the surgical setting.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Hawn, M. T., Graham, L. A., Richman, J. R., Itani, K. M., Plomondon, M. E., Altom, L. K., et al. (2012). The incidence and timing of noncardiac surgery after cardiac stent implantation. Journal of the American College of Surgery, 214, 658–666.

    Article  Google Scholar 

  2. Wright, R. S., Anderson, J. L., Adams, C. D., Bridges, C. R., Casey, D. E., Jr., Ettinger, S. M., et al. (2011). 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/ Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation, 123, 2022–2060.

    Article  PubMed  Google Scholar 

  3. Hamm, C. W., Bassand, J. P., Agewall, S., Bax, J., Boersma, E., Bueno, H., et al. (2011). ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal, 32, 2999–3054.

    Article  PubMed  Google Scholar 

  4. Wijns, W., Kolh, P., Danchin, N., Di Mario, C., Falk, V., Folliguet, T., et al. (2010). Guidelines on myocardial revascularization. European Heart Journal, 31, 2501–2555.

    Article  PubMed  Google Scholar 

  5. Rossini, R., Capodanno, D., Lettieri, C., Musumeci, G., Nijaradze, T., Romano, M., et al. (2011). Prevalence, predictors, and long-term prognosis of premature discontinuation of oral antiplatelet therapy after drug eluting stent implantation. The American Journal of Cardiology, 107, 186–194.

    Article  CAS  PubMed  Google Scholar 

  6. Kaluza, G. L., Joseph, J., Lee, J. R., Raizner, M. E., & Raizner, A. E. (2000). Catastrophic outcomes of noncardiac surgery soon after coronary stenting. Journal of the American College of Cardiology, 35, 1288–1294.

    Article  CAS  PubMed  Google Scholar 

  7. Sharma, A. K., Ajani, A. E., Hamwi, S. M., Maniar, P., Lakhani, S. V., Waksman, R., et al. (2004). Major noncardiac surgery following coronary stenting: when is it safe to operate? Catheterization and Cardiovascular Interventions, 63, 141–145.

    Article  PubMed  Google Scholar 

  8. Wilson, S. H., Fasseas, P., Orford, J. L., Lennon, R. J., Horlocker, T., Charnoff, N. E., et al. (2003). Clinical outcome of patients undergoing noncardiac surgery in the two months following coronary stenting. Journal of the American College of Cardiology, 42, 234–240.

    Article  PubMed  Google Scholar 

  9. Reddy, P. R., & Vaitkus, P. T. (2005). Risks of noncardiac surgery after coronary stenting. The American Journal of Cardiology, 95, 755–757.

    Article  PubMed  Google Scholar 

  10. Vicenzi, M. N., Meislitzer, T., Heitzinger, B., Halaj, M., Fleisher, L. A., & Metzler, H. (2006). Coronary artery stenting and noncardiac surgery—a prospective outcome study. British Journal of Anaesthesia, 96, 686–693.

    Article  CAS  PubMed  Google Scholar 

  11. McFadden, E. P., Stabile, E., Regar, E., Cheneau, E., Ong, A. T., Kinnaird, T., et al. (2004). Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet, 364, 1519–1521.

    Article  CAS  PubMed  Google Scholar 

  12. Nasser, M., Kapeliovich, M., & Markiewicz, W. (2005). Late thrombosis of sirolimus- eluting stents following noncardiac surgery. Catheterization and Cardiovascular Interventions, 65, 516–519.

    Article  PubMed  Google Scholar 

  13. Bakhru, M., Saber, W., Brotman, D., Bhatt, D., Angja, A., Tillan-Martinez, K., et al. (2006). Is discontinuation of antiplatelet therapy after 6 months safe in patients with drug-eluting stents undergoing noncardiac surgery? Cleveland Clinic Journal of Medicine, 73, S23.

    Article  Google Scholar 

  14. Compton, P. A., Zankar, A. A., Adesanya, A. O., Banerjee, S., & Brilakis, E. S. (2006). Risk of noncardiac surgery after coronary drug-eluting stent implantation. The American Journal of Cardiology, 98, 1212–1213.

    Article  PubMed  Google Scholar 

  15. Schouten, O., vanDomburg, R. T., Bax, J. J., de Jaegere, P. J., Dunkelgrun, M., Feringa, H. H., et al. (2007). Noncardiac surgery after coronary stenting: early surgery and interruption of antiplatelet therapy are associated with an increase in major adverse cardiac events. Journal of the American College of Cardiology, 49, 122–124.

    Article  PubMed  Google Scholar 

  16. Gandhi, N. K., Abdel-Karim, A. R., Banerjee, S., & Brilakis, E. S. (2011). Frequency and risk of noncardiac surgery after drug-eluting stent implantation. Catheterization and Cardiovascular Interventions, 77, 972–976.

    Article  PubMed  Google Scholar 

  17. Brilakis, E. S., Cohen, D. J., Kleiman, N. S., Pencina, M., Nassif, D., Saucedo, J., et al. (2011). Incidence and clinical outcome of minor surgery in the year after drug-eluting stent implantation: results from the Evaluation of Drug-Eluting Stents and Ischemic Events Registry. American Heart Journal, 161, 360–366.

    Article  PubMed  Google Scholar 

  18. Layland, J., Jellis, C., & Whitbourn, R. (2009). Extremely late drug-eluting stent thrombosis: 2037 days after deployment. Cardiovascular Revascularization Medicine, 10, 55–57.

    Article  PubMed  Google Scholar 

  19. Iakovou, I., Schmidt, T., Bonizzoni, E., Ge, L., Sangiorgi, G. M., Stankovic, G., et al. (2005). Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. Journal of the American Medical Association, 293, 2126–2130.

    Article  CAS  PubMed  Google Scholar 

  20. Parolari, A., Mussoni, L., Frigerio, M., Naliato, M., Alamanni, F., Galanti, A., et al. (2005). Increased prothrombotic state lasting as long as one month after on-pump and off-pump coronary surgery. The Journal of Thoracic and Cardiovascular Surgery, 130, 303–308.

    Article  PubMed  Google Scholar 

  21. Chimienti, G., Mezzapesa, A., Rotelli, M. T., Lupo, L., & Pepe, G. (2012). Plasma concentrations but not serum concentrations of brain-derived neurotrophic factor are related to pro-inflammatory cytokines in patients undergoing major abdominal surgery. Clinical Biochemistry, 45, 631–636.

    Article  CAS  PubMed  Google Scholar 

  22. Lin, M. T., Yeh, S. L., Wu, M. S., Lin, J. T., Lee, P. H., Liaw, K. Y., et al. (2009). Impact of surgery on local and systemic responses of cytokines and adhesion molecules. Hepato-Gastroenterology, 56, 1341–1345.

    CAS  PubMed  Google Scholar 

  23. Berger, P. B., Kleiman, N. S., Pencina, M. J., Hsieh, W. H., Steinhubl, S. R., Jeremias, A., et al. (2010). Frequency of major noncardiac surgery and subsequent adverse events in the year after drug-eluting stent placement results from the EVENT (Evaluation of Drug-Eluting Stents and Ischemic Events) Registry. JACC. Cardiovascular Interventions, 3, 920–927.

    Article  PubMed  Google Scholar 

  24. Anwaruddin, S., Askari, A. T., Saudye, H., Batizy, L., Houghtaling, P. L., Alamoudi, M., et al. (2009). Characterization of post-operative risk associated with prior drug-eluting stent use. JACC. Cardiovascular Interventions, 2, 542–549.

    Article  PubMed  Google Scholar 

  25. Wijeysundera, D. N., Wijeysundera, H. C., Yun, L., Wąsowicz, M., Beattie, W. S., Velianou, J. L., et al. (2012). Risk of elective major noncardiac surgery after coronary stent insertion: a population-based study. Circulation, 126, 1355–1362.

    Article  PubMed  Google Scholar 

  26. Fleisher, L. A., Beckman, J. A., Brown, K. A., Calkins, H., Chaikof, E. L., Fleischmann, K. E., et al. (2007). ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. Circulation, 116, 1971–1996.

    Article  PubMed  Google Scholar 

  27. Grines, C. L., Bonow, R. O., Casey, D. E., Jr., Gardner, T. J., Lockhart, P. B., Moliterno, D. J., et al. (2007). Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation, 115, 813–818.

    Article  PubMed  Google Scholar 

  28. Hawn, M. T., Graham, L. A., Richman, J. S., Itani, K. M., Henderson, W. G., & Maddox, T. M. (2013). Risk of major adverse cardiac events following noncardiac surgery in patients with coronary stents. Journal of the American Medical Association, 310, 1462–1472.

    Article  CAS  PubMed  Google Scholar 

  29. Smith, P. K., Goodnough, L. T., Levy, J. H., Poston, R. S., Short, M. A., Weerakkody, G. J., et al. (2012). Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. Journal of the American College of Cardiology, 60, 388–396.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  30. Collet, J. P., Montalescot, G., Blanchet, B., Tanguy, M. L., Golmard, J. L., Choussat, R., et al. (2004). Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes. Circulation, 110, 2361–2367.

    Article  CAS  PubMed  Google Scholar 

  31. Lordkipanidzé, M., Diodati, J. G., & Pharand, C. (2009). Possibility of a rebound phenomenon following antiplatelet therapy withdrawal: a look at the clinical and pharmacological evidence. Pharmacology and Therapeutics, 123, 178–186.

    Article  PubMed  Google Scholar 

  32. Capodanno, D., Patel, A., Dharmashankar, K., Ferreiro, J. L., Ueno, M., Kodali, M., et al. (2011). Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. Circulation. Cardiovascular Interventions, 4, 180–187.

    Article  CAS  PubMed  Google Scholar 

  33. Weber, A. A., Braun, M., Hohlfeld, T., Schwippert, B., Tschöpe, D., & Schrör, K. (2001). Recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers. British Journal of Clinical Pharmacology, 52, 333–336.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  34. Angiolillo, D. J., Fernandez-Ortiz, A., Bernardo, E., Ramírez, C., Sabaté, M., Jimenez-Quevedo, P., et al. (2006). Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease. Diabetes, 55, 780–784.

    Article  CAS  PubMed  Google Scholar 

  35. Frelinger, A. L., 3rd, Barnard, M. R., Fox, M. L., & Michelson, A. D. (2010). The platelet activity after clopidogrel termination (PACT) study. Circulation. Cardiovascular Interventions, 3, 442–449.

    Article  CAS  PubMed  Google Scholar 

  36. Sibbing, D., Stegherr, J., Braun, S., Mehilli, J., Schulz, S., Seyfarth, M., et al. (2010). A double-blind, randomized study on prevention and existence of a rebound phenomenon of platelets after cessation of clopidogrel treatment. Journal of the American College of Cardiology, 55, 558–565.

    Article  CAS  PubMed  Google Scholar 

  37. Mehran, R., Baber, U., Steg, P. G., Ariti, C., Weisz, G., Witzenbichler, B., et al. (2013). Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet, 30.

  38. Ferreira-González, I., Marsal, J. R., Ribera, A., Permanyer-Miralda, G., García-Del Blanco, B., Martí, G., et al. (2012). Double antiplatelet therapy after drug-eluting stent implantation: risk associated with discontinuation within the first year. Journal of the American College of Cardiology, 60, 1333–1339.

    Article  PubMed  Google Scholar 

  39. Eisenberg, M. J., Richard, P. R., Libersan, D., & Filion, K. B. (2009). Safety of short-term discontinuation of antiplatelet therapy in patients with drug-eluting stents. Circulation, 119, 1634–1642.

    Article  CAS  PubMed  Google Scholar 

  40. Lindblad, B., Persson, N. H., Takolander, R., & Bergqvist, D. (1993). Does low-dose acetylsalicylic acid prevent stroke after carotid surgery? A double-blind, placebo-controlled randomized trial. Stroke, 24, 1125–1128.

    Article  CAS  PubMed  Google Scholar 

  41. Douketis, J. D., Spyropoulos, A. C., Spencer, F. A., Mayr, M., Jaffer, A. K., Eckman, M. H., et al. (2012). Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 141(Suppl), e326S–e350S.

    CAS  PubMed  Google Scholar 

  42. Karkouti, K., McCluskey, S. A., Syed, S., Pazaratz, C., Poonawala, H., & Crowther, M. A. (2010). The influence of perioperative coagulation status on postoperative blood loss in complex cardiac surgery: a prospective observational study. Anesthesia and Analgesia, 110, 1533–1540.

    Article  PubMed  Google Scholar 

  43. Oscarsson, A., Gupta, A., Fredrikson, M., Järhult, J., Nyström, M., Pettersson, E., et al. (2010). To continue or discontinue aspirin in the perioperative period: a randomized, controlled clinical trial. British Journal of Anaesthesia, 104, 305–312.

    Article  CAS  PubMed  Google Scholar 

  44. Burger, W., Chemnitius, J. M., Kneissl, G. D., & Rücker, G. (2005). Low- dose aspirin for secondary cardiovascular prevention—cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation—review and meta-analysis. Journal of Internal Medicine, 257, 399–414.

    Article  CAS  PubMed  Google Scholar 

  45. Sun, J. C., Whitlock, R., Cheng, J., Eikelboom, J. W., Thabane, L., Crowther, M. A., et al. (2008). The effect of pre-operative aspirin on bleeding, transfusion, myocardial infarction, and mortality in coronary artery bypass surgery: a systematic review of randomized and observational studies. European Heart Journal, 29, 1057–1071.

    Article  PubMed  Google Scholar 

  46. Lorenz, R. L., Schacky, C. V., Weber, M., Meister, W., Kotzur, J., Reichardt, B., et al. (1984). Improved aortocoronary bypass patency by low-dose aspirin (100 mg daily). Effects on platelet aggregation and thromboxane formation. Lancet, 1, 1261–1264.

    Article  CAS  PubMed  Google Scholar 

  47. Sharma, G. V., Khuri, S. F., Josa, M., Folland, E. D., & Parisi, A. F. (1983). The effect of antiplatelet therapy on saphenous vein coronary artery bypass graft patency. Circulation, 68, 218–221.

    Google Scholar 

  48. Yusuf, S., Zhao, F., Mehta, S. R., Chrolavicius, S., Tognoni, G., Fox, K. K., et al. (2001). Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. The New England Journal of Medicine, 345, 494–502.

    Article  CAS  PubMed  Google Scholar 

  49. Fox, K. A., Mehta, S. R., Peters, R., Zhao, F., Lakkis, N., Gersh, B. J., et al. (2004). Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation, 110, 1202–1208.

    Article  CAS  PubMed  Google Scholar 

  50. Ernst, A., Eberhardt, R., Wahidi, M., Becker, H. D., & Herth, F. J. (2006). Effect of routine clopidogrel use on bleeding complications after transbronchial biopsy in humans. Chest, 129, 734–737.

    Article  PubMed  Google Scholar 

  51. Miceli, A., Duggan, S. M., Aresu, G., de Siena, P. M., Romeo, F., Glauber, M., et al. (2013). Combined clopidogrel and aspirin treatment up to surgery increases the risk of postoperative myocardial infarction, blood loss and reoperation for bleeding in patients undergoing coronary artery bypass grafting. European Journal of Cardio-Thoracic Surgery, 43, 722–728.

    Article  PubMed  Google Scholar 

  52. Berger, J. S., Herout, P. M., Harshaw, Q., Steinhubl, S. R., Frye, C. B., & Becker, R. C. (2012). Bleeding-associated outcomes with preoperative clopidogrel use in on- and off-pump coronary artery bypass. Journal of Thrombosis and Thrombolysis, 34, 56–64.

    Article  CAS  PubMed  Google Scholar 

  53. Bittner, H. B., Lehmann, S., Rastan, A., & Mohr, F. W. (2012). Impact of clopidogrel on bleeding complications and survival in off-pump coronary artery bypass grafting. Interactive Cardiovascular and Thoracic Surgery, 14, 273–277.

    Article  PubMed  Google Scholar 

  54. Biancari, F., Airaksinen, K. E., & Lip, G. Y. (2012). Benefits and risks of using clopidogrel before coronary artery bypass surgery: systematic review and meta-analysis of randomized trials and observational studies. The Journal of Thoracic and Cardiovascular Surgery, 143, 665–675.

    Article  CAS  PubMed  Google Scholar 

  55. Nijjer, S. S., Watson, G., Athanasiou, T., & Malik, I. S. (2011). Safety of clopidogrel being continued until the time of coronary artery bypass grafting in patients with acute coronary syndrome: a meta-analysis of 34 studies. European Heart Journal, 32, 2970–2988.

    Article  CAS  PubMed  Google Scholar 

  56. Nijjer, S. S., Athanasiou, T., & Malik, I. S. (2012). Conflicting meta-analytic results: potential for confusion if left unexplained. The Journal of Thoracic and Cardiovascular Surgery, 143, 247–248.

    Article  PubMed  Google Scholar 

  57. Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., et al. (2007). Prasugrel versus clopidogrel in patients with acute coronary syndromes. The New England Journal of Medicine, 357, 2001–2015.

    Article  CAS  PubMed  Google Scholar 

  58. Food and Drug Administration. Effient, full prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022307s007lbl.pdf.

  59. European Medicines Agency. Efient, summary of product characteristics. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000984/WC500021971.pdf.

  60. Price, M. J., Walder, J. S., Baker, B. A., Heiselman, D. E., Jakubowski, J. A., Logan, D. K., et al. (2012). Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial. Journal of the American College of Cardiology, 59, 2338–2343.

    Article  CAS  PubMed  Google Scholar 

  61. Bernlochner, I., Morath, T., Brown, P. B., Zhou, C., Baker, B. A., Gupta, N., et al. (2013). A prospective randomized trial comparing the recovery of platelet function after loading dose administration of prasugrel or clopidogrel. Platelets, 24, 15–25.

    Article  CAS  PubMed  Google Scholar 

  62. Held, C., Asenblad, N., Bassand, J. P., Becker, R. C., Cannon, C. P., Claeys, M. J., et al. (2011). Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. Journal of the American College of Cardiology, 57, 672–684.

    Article  CAS  PubMed  Google Scholar 

  63. Gurbel, P. A., Bliden, K. P., Butler, K., Tantry, U. S., Gesheff, T., Wei, C., et al. (2009). Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation, 120, 2577–2585.

    Article  CAS  PubMed  Google Scholar 

  64. Varenhorst, C., Alström, U., Scirica, B. M., Hogue, C. W., Åsenblad, N., Storey, R. F., et al. (2012). Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery. Journal of the American College of Cardiology, 60, 1623–1630.

    Article  PubMed  Google Scholar 

  65. Food and Drug Administration. Brilinta, full prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022433s008lbl.pdf.

  66. European Medicines Agency. Efient, summary of product characteristics. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001241/WC500100494.pdf.

  67. Hillis, L. D., Smith, P. K., Anderson, J. L., Bittl, J. A., Bridges, C. R., Byrne, J. G., et al. (2011). 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons. Circulation, 124, 652–735.

    Article  Google Scholar 

  68. Mehta, S. R., Yusuf, S., Peters, R. J., Bertrand, M. E., Lewis, B. S., Natarajan, M. K., et al. (2001). Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial (CURE) Investigators et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet, 358, 527–533.

    Article  CAS  PubMed  Google Scholar 

  69. Albaladejo, P., Marret, E., Samama, C. M., Collet, J. P., Abhay, K., Loutrel, O., et al. (2011). Non-cardiac surgery in patients with coronary stents: the RECO study. Heart, 97, 1566–1572.

    Article  PubMed  Google Scholar 

  70. Lincoff, A. M., LeNarz, L. A., Despotis, G. J., Smith, P. K., Booth, J. E., Raymond, R. E., et al. (2000). Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT trials. Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibition in STENTing. The Annals of Thoracic Surgery, 70, 516–526.

    Article  CAS  PubMed  Google Scholar 

  71. Sim, D. S., Merrill-Skoloff, G., Furie, B. C., Furie, B., & Flaumenhaft, R. (2004). Initial accumulation of platelets during arterial thrombus formation in vivo is inhibited by elevation of basal cAMP levels. Blood, 103, 2127–2134.

    Article  CAS  PubMed  Google Scholar 

  72. Hirsh, J., Warkentin, T. E., Shaughnessy, S. G., Anand, S. S., Halperin, J. L., Raschke, R., et al. (2001). Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest, 119, 64–94.

    Article  Google Scholar 

  73. Savonitto, S., D’Urbano, M., Caracciolo, M., Barlocco, F., Mariani, G., Nichelatti, M., et al. (2010). Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of ‘bridging’ antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel. British Journal of Anaesthesia, 104, 285–291.

    Article  CAS  PubMed  Google Scholar 

  74. Alshawabkeh, L. I., Prasad, A., Lenkovsky, F., Makary, L. F., Kandil, E. S., Weideman, R. A., et al. (2013). Outcomes of a preoperative "bridging" strategy with glycoprotein IIb/IIIa inhibitors to prevent perioperative stent thrombosis in patients with drug-eluting stents who undergo surgery necessitating interruption of thienopyridine administration. EuroIntervention, 9, 204–211.

    Article  PubMed  Google Scholar 

  75. Angiolillo, D. J., Firstenberg, M. S., Price, M. J., Tummala, P. E., Hutyra, M., Welsby, I. J., et al. (2012). Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. Journal of the American Medical Association, 307, 265–74.

    CAS  PubMed Central  PubMed  Google Scholar 

  76. Bhatt, D. L., Stone, G. W., Mahaffey, K. W., Gibson, C. M., Steg, P. G., Hamm, C. W., et al. (2013). Effect of platelet inhibition with cangrelor during PCI on ischemic events. The New England Journal of Medicine, 368, 1303–1313.

    Article  CAS  PubMed  Google Scholar 

  77. Steg, P. G., Bhatt, D. L., Hamm, C. W., Stone, G. W., Gibson, C. M., Mahaffey, K. W., et al. (2013). Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet, 2.

Download references

Disclosures

Davide Capodanno has received payments as an individual for consulting fee or honorarium from Eli Lilly, Daiichi Sankyo, The Medicines Company, AstraZeneca.

Author information

Authors and Affiliations

  1. Ferrarotto Hospital, University of Catania, Via Citelli, 6, 95124, Catania, Italy

    Davide Capodanno & Corrado Tamburino

Authors
  1. Davide Capodanno
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Corrado Tamburino
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Davide Capodanno.

Additional information

Associate Editor Dominick Angiolillo oversaw the review of this article.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Capodanno, D., Tamburino, C. Bridging antiplatelet therapy in patients requiring cardiac and non-cardiac surgery: from bench to bedside. J. of Cardiovasc. Trans. Res. 7, 82–90 (2014). https://doi.org/10.1007/s12265-013-9517-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12265-013-9517-5

Keywords

Search

Navigation